Benefits of Afatinib and Osimertinib in a Patient with Lung Adenocarcinoma Harboring EGFR19Del/T790M/ G724S Mutation

被引：0
|
作者：
Lyu, X. [1 ]
Jiao, T. [1 ]
Yang, S. [1 ]
Yang, S. [1 ]
机构：
[1] Xi An Jiao Tong Univ, Affiliated Hosp 2, Xian, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
lung adenocarcinoma; targeted therapy; EGFR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-08
引用
收藏
页码：S643 / S643
页数：1
相关论文
共 50 条
  • [31] PREDICTIVE FACTORS OF OSIMERTINIB AS SALVAGE TREATMENT FOR METASTATIC EGFR T790M POSITIVE LUNG ADENOCARCINOMA
    Park, Ji Young
    Jang, Seung Hun
    Kim, Hwan Il
    Kim, Joo-Hee
    Park, Sunghoon
    Hwang, Yong Il
    Jung, Ki-Suck
    Seo, Jinwon
    RESPIROLOGY, 2019, 24 : 177 - 177
  • [32] Effect of osimertinib treatment on lung adenocarcinoma with squamous cell transformation harboring the T790M mutation: A case report and literature review
    Yamaguchi, Fumihiro
    Kato, Eisuke
    Wakabayashi, Aya
    Shikama, Yusuke
    MOLECULAR AND CLINICAL ONCOLOGY, 2019, 11 (02) : 127 - 131
  • [33] Efficacy of afatinib in a patient with rare EGFR(G724S/R776H) mutations and amplification in lung adenocarcinoma:A case report
    Shu-Yan He
    Qing-Feng Lin
    Jie Chen
    Gui-Ping Yu
    Jun-Ling Zhang
    Dong Shen
    World Journal of Clinical Cases, 2021, 9 (06) : 1329 - 1335
  • [34] Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report
    He, Shu-Yan
    Lin, Qing-Feng
    Chen, Jie
    Yu, Gui-Ping
    Zhang, Jun-Ling
    Shen, Dong
    WORLD JOURNAL OF CLINICAL CASES, 2021, 9 (06) : 1329 - 1335
  • [35] CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation
    Kashima, Kenji
    Kawauchi, Hiroki
    Tanimura, Hiromi
    Tachibana, Yukako
    Chiba, Takashi
    Torizawa, Takuya
    Sakamoto, Hiroshi
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (11) : 2288 - 2297
  • [36] Clinicopathologic features of lung cancer patients harboring de novo EGFR T790M mutation
    Lee, Young Joo
    Lee, Geon Kook
    Lee, Yeon-Su
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies
    Cortiula, Francesco
    Pelizzari, Giacomo
    Corvaja, Carla
    De Maglio, Giovanna
    Fasola, Gianpiero
    ANTI-CANCER DRUGS, 2022, 33 (09) : 960 - 962
  • [38] Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy
    Wang, Xiaofei
    Zhou, Ling
    Yin, Jiani C.
    Wu, Xue
    Shao, Yang W.
    Gao, Beili
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (05) : E85 - E88
  • [39] Osimertinib shows promise in treating choroidal metastases and improving vision in EGFR T790M mutation-positive lung adenocarcinoma
    Keshwani, K.
    Roelofs, K.
    Hay, G.
    Lewis, R.
    Plowman, P.
    LUNG CANCER, 2020, 139 : S94 - S94
  • [40] In vivo efficacy of triplet therapy with osimertinib, cetuximab and bevacizumab for lung cancer cells harboring EGFR T790M
    Nishii, Kazuya
    Ohashi, Kadoaki
    Makimoto, Go
    Higo, Hisao
    Ninomiya, Kiichiro
    Kayatani, Hiroe
    Ninomiya, Takashi
    Kubo, Toshio
    Rai, Kammei
    Ichihara, Eiki
    Hotta, Katsuyuki
    Tabata, Masahiro
    Kiura, Katsuyuki
    CANCER RESEARCH, 2018, 78 (13)
12345